Problem

Lucis addresses the gap between having health data and knowing what to do with it. Conventional blood testing can produce isolated measurements that are difficult for individuals to interpret or connect to longer-term trends, making preventive action feel reactive, fragmented, or inaccessible. The core use case is helping someone understand their underlying biology, identify what matters across multiple body systems, and make more informed health decisions before a problem becomes acute. Lucis explicitly positions itself as a health companion rather than a replacement for medical diagnosis or prescriptions.

Product / Service

Lucis is a paid preventive-health membership that combines blood biomarker analysis with an AI-powered platform delivering personalised, science-based recommendations. Its current offering is listed at €490 annually and includes blood, saliva, and urine testing, 110 markers in the first test, 60 in the second, coverage across 11 body systems, wearable integration, and access to laboratories across Europe. The platform translates test results into an ongoing, data-driven view of health, supported by clinician review tools and a network of physicians, so members can track trends and act on relevant changes rather than simply receive a laboratory report.

Market

Lucis competes in the European consumer preventive-health and predictive-health market, at the intersection of biomarker testing, digital health coaching, and personalised wellness. The available research does not identify named direct competitors, but Lucis’s positioning differentiates it from a one-off testing service by combining recurring testing, AI interpretation, longitudinal health tracking, and personalised recommendations. Its €490 annual price indicates a commercial subscription model rather than a purely pre-revenue concept.

The company launched in 2025 and, by May 2026, reported more than 10,000 users across France, the UK, Ireland, and Portugal. It also reported a $20 million Series A led by Singular, with participation from General Catalyst and Y Combinator, alongside a team of 20 and a growing network of more than 10 physicians. That combination of paid pricing, international users, institutional funding, and clinical infrastructure suggests meaningful early traction, although the available evidence does not provide revenue, retention, or outcome metrics.